CRNX: Crinetics Pharmaceuticals Company Short-Term Debt

Symbol and logo of brand Crinetics Pharmaceuticals (CRNX)

Crinetics Pharmaceuticals (CRNX) develops oral therapies for rare endocrine pathologies, targeting high-margin B2B and B2C segments. The perpetual sales cycle of proprietary products ensures stable demand, as confirmed by the short-term debt valuation shown on this chart from GURU.Markets. An innovative R&D pipeline featuring paltusineg promises to replace injections with tablets, while 0.01 serves as the final level mark.

CRNX (Crinetics Pharmaceuticals, Inc.) Company Short-Term Debts history from 07/04/2022 to 09/12/2026

CRNX (Crinetics Corp): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart Crinetics|CRNX - Fair Value Consensus
- market capitalization information:
Market Value Crinetics Pharmaceuticals|CRNX - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Crinetics|CRNX - Book Capitalization|Market Cap to Net Assets Ratio crinetics.com|CRNX - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Crinetics Pharmaceuticals|CRNX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Crinetics Pharmaceuticals|CRNX - Company Cumulative Debt|Debt to Book Value Crinetics Pharmaceuticals|CRNX - Amount of Long-Term Liabilities|Company Short-Term Debts Crinetics|Quick Ratio crinetics.com
- net income and valuation multiples indicators:
CRNX - Company Net Income
Basic company analysis:Crinetics - CRNX
Mass-produced product of Crinetics Corp

This indicator measures total liabilities with a maturity of up to one year, reflecting the ability of cash flows to cover operating expenses and current loans. For Crinetics Pharmaceuticals (CRNX), which utilizes third-party manufacturing sites, this metric is critical for contractor settlements; therefore, analyzing the level of short-term liabilities allows for an assessment of the financial stability of the outsourcing model.

Who Crinetics Pharmaceuticals competes with

ASND - Company Short-Term Debt|Company Short-Term Loans and Borrowings MDGL (Madrigal Pharmaceuticals Inc)|Corcept (CORT) - Company Short-Term Debt|Company Current Liabilities Rhythm Corp|AKRO (Akero Therapeutics) - Company Short-Term Debts|Company Short-Term Debts metsera.com|Company Current Liabilities MLTX (MoonLake)|NAMS (NewAmsterdam Pharma Company) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Soleno SLNO|FOLD - Company Current Liabilities|89bio, Inc. - Company Short-Term Debts|Short-Term Debt agios.com|GPCR (Structure Therapeutics Inc.) - Company Current Liabilities|MDXG: Amount of Current Liabilities|RZLT (Rezolute Corp) - Company Short-Term Debts|Company Short-Term Debts Lexicon Corp|Company Short-Term Debts MBX|Company Short-Term Debt ALT (altimmune.com)|Company Short-Term Debt Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. (SGMT) - Short-Term Debt|BIOA - Company Short-Term Debt|BMEA: Company Short-Term Debt|QNCX: Company Short-Term Debts|GUTS - Short-Term Debt Volume|Company Short-Term Debt vTv Therapeutics, Inc.|Agape ATP Corp. (ATPC) - Short-Term Debt Volume|Company Short-Term Debt Pluri Inc. (PLUR)|Company Current Liabilities synlogictx.com SYBX|Company Short-Term Debts LPCN (Lipocine Inc.)|MTNB - Company Current Liabilities|SPRB - Company Short-Term Debt|Company Short-Term Loans and Borrowings GLTO (Galecto Inc)|CTCX: Company Short-Term Debts|LUMO - Short-Term Debt Volume|Company Short-Term Debt Organovo Holdings, Inc.|Company Short-Term Indebtedness RDUS (radiuspharm.com)